Introduction
The ets family of genes was originally discovered by its homology to the avian transforming virus E26 (Nunn et al., 1984; Bister et al., 1982) and is characterized by a conserved DNA binding domain (Watson et al., 1988; Karim et al., 1990) which recognize the GGA A/T motif (Macleod et al., 1992; Wasylyk et al., 1993; Werner et al., 1995; Kodandapani et al., 1996) . Ets genes have been found throughout the metazoan evolution (Lautenberger et al., 1992; Laudet et al., 1993; Degnan et al., 1993) which is suggestive of their fundamental role. They have been implicated in cellular proliferation and tumorigenesis (Macleod et al., 1992; Wasylyk et al., 1993; Seth et al., 1992; Janknecht and Nordheim, 1993) and have been suggested to be involved in the regulation of key cellular genes as cfos (Karin, 1994; Treisman, 1994) , c-myc (Roussel et al., 1994) , Rb (Savoysky et al., 1994) and ETS2 . They have been found to cooperate with other cellular transcription factors in early mitogenic response (Treier et al., 1995; Sieweke et al., 1996) and have been suggested to be downstream eectors in the ras/MAPK signalling pathway (Janknecht and Nordheim, 1993; Yang et al., 1996; Janknecht, 1996; Gille et al., 1992; Hill et al., 1993; Marais et al., 1993; O'Neill et al., 1994; Rao and Reddy, 1994; Brunner et al., 1994) and regulated by MAPK. The data suggesting a possible association of ets genes with proliferative processes have been supported by the identi®cation of ets genes at chromosomal breakpoints, which result in ets gene rearrangement in certain human malignancies. Fli1 has been identi®ed in 11;22 translocation of Ewing's Sarcoma Delattre et al., 1992) and peripheral neuroepithelioma (Hromas et al., 1993; Hromas and Klemsz, 1994) . The ERG gene in 21;22 translocation in Ewing's Sarcoma (Sorensen et al., 1994) and 16;21 translocation in AML (Shimizu et al., 1993; Panagopoulos et al., 1994) , the ETV1 in 7;22 Ewing's Sarcoma translocation (Jeon et al., 1995) and the TEL gene in 5;12 and 22;12 translocations in myoproliferative disorders (Buijs et al., 1995; Wlodarska et al., 1995) . Finally, it recently has been shown that overexpression of ets2 in mice can partially mimic the Down Syndrome phenotype (Sumarsono et al., 1996) .
ERF is a novel member of the ets family that has been isolated by its interaction with the ETS2 promoter (Sgouras et al., 1995) . It has no similarity to other ets genes outside the DNA-binding domain; the family member most similar to ERF is PE-1 . ERF is ubiquitously expressed, exhibits strong transcriptional repressor activity and has been shown to be regulated by phosphorylation throughout the cell cycle and during mitogenic stimulation. Furthermore, is capable of suppressing ets and fos induced tumorigenicity in the NIH3T3 system and may act as a tumor suppressor gene.
To further analyse ERF's function and its possible implication in malignancies, we isolated both the human and mouse genes and analysed their structure and organization. Both genes have identical intron/exon boundaries although the intron sizes are slightly dierent. The genes are 90% indentical within their coding region at the nucleotide level and 98% identical at the amino acid level. Interestingly, most of the dierences appear at the carboxy terminus, which harbors the transcriptional repressor domain. Both genes are driven of a promoter with a high GC content; this is consistent with their ubiquitous expression. Interestingly, the proximal promoter region between the two species is as homologous as the rest of the coding region, i.e. about 91%. The human gene is localized on chromosome 19q13.1, while the mouse gene in the syntenic region on mouse chromosome 7. The chromosomal position of ERF suggests a possible implication in certain human malignancies and makes it a target for future investigation.
Results

Isolation and characterization of ERF gene from human and mouse
We utilized the ERF cDNA to screen both a human cosmid library (Strategene, La Jolla, CA) and a mouse C127 library (Stratagene, La Jolla, CA). Two overlapping cosmid clones were isolated for the human gene and a phage clone for the mouse gene (Figure 1 ) that contained the entire erf gene. The intron/exon organization of both genes was determined by restriction mapping and dideoxy sequencing utilizing primers derived from the human cDNA sequence as well as new ones derived from the determined mouse sequence. The gene in both species consists of 4 exons, the 2nd and 3rd of which are coding for the ets DNA binding domain. The last three exons are separated by very small introns (88 ± 387 bp) in contrast to the ®rst intron that is *5 kb (Figure 2 ). The intron/exon splice junctions are identical in both genes. The overall nucleotide identity between the human and the mouse gene is 90% within the coding region ( Figure 3B and drops to 50 ± 60% within the sequenced introns and the 3' untranslated regions (not shown).
The deduced amino acid sequence of the mouse gene is 98% homologous to the human gene ( Figure 3A) , although the mouse protein is three amino acids longer than the human protein (551 versus 549 aa). The proteins are identical within the DNA binding domain and all of the seven putative MAP kinase sites can also be found within the mouse sequence at exactly the same positions. Interestingly, six out of the 10 non-conservative mutations can be found within the repressor domain of ERF genes (amino acids 476 ± 529 of the human protein).
Promoter analysis
In order to determine if the previously identi®ed ERF cDNA contained the entire ERF mRNA, we analysed the genomic DNA sequence surrounding the 5' end of the ERF cDNA for its ability to function as a promoter. Immediately upstream from the area that corresponds to the 5' end of the cDNA, there is a putative TATA element conserved both in mouse ( Figure 2A ) and human ( Figure 5A ). This area has a very high GC content consistent with the promoter of a ubiquitously expressed gene, such as ERF. Indeed, ERF can be detected in all cell lines and tissues tested, similar levels, when compared to actin mRNA ( Figure 4 ).
There is a remarkable homology between the mouse and the human gene within the 250 bp region upstream of the putative initiation point. The extent of homology is equivalent to that of the coding region, i.e. *91% ( Figure 3C ). In addition to the TATA box, a number of other putative transcription factor binding sites are conserved in sequence and relative position between the two species, including two Sp1 sites, one CREB/ATF site and one ets binding site (EBS). The EBS site within the mouse promoter is actually 13 bp upstream of the corresponding position within the human promoter ( Figure 3C ). We tested the ability of a 330 bp fragment of the human gene that harbors the area that corresponds to the 5' end of the cDNA, to function as a promoter after transfection in HeLa cells. As shown in Figure  5B , this fragment exhibited an orientation-speci®c promoter function. The promoter strength of this fragment was 50% of the ETS2 promoter (Mavrothalassitis et al., 1990a,b) when tested in the same vector, cells and under the same conditions (data not shown). This is consistent with the relative mRNA levels of ERF and ETS2 in HeLa cells (not shown). Interestingly, when an 80 bp fragment that contains the putative ets binding site and one Sp1 was removed, . A schematic representation of the ERF promoter region and the reporter constructs used to determine promoter activity. Promoter strength is expressed as a percentile of the activity of the 332 bp SacII fragment. Striped box indicates the position of the putative TATA box the promoter activity was dramatically reduced, suggesting that this area is important for the promoter function in this cell type.
Chromosomal localization
The ability of the ERF gene to suppress ets-induced tumorigenesis suggested that it may have some tumor suppressor function. To identify possible human malignancies which may be associated with ERF function, we determined its chromosomal position in both human and mouse. Southern analysis with an ERF-speci®c probe of somatic cell hybrid panels (BIOS Corp., New Haven, CT) revealed that ERF is localized on human chromosome 19 (data not shown). For the regional assignment of ERF, we performed¯uorescent in situ hybridization (FISH) analysis using both cosmids no. 7 and no. 20 (Figure 1) carrying the human ERF gene as a probe. A total of 67 metaphase cells were examined. Twenty-®ve of these cells revealed paired hybridization signals and an additional 24 cells exhibited single signals at chromosomal region 19q13.1. Consistent background hybridization was not observed at any other speci®c chromosomal position ( Figure 6 ).
In addition to the mapping of the human gene, we have determined the chromosomal position of Erf in mice by linkage analysis. We performed genotypic analysis of about 60 random back-cross progeny mice using a mouse Erf probe that can detect a Taq1 polymorphism in Mus spretus and C57BL/6 genomic DNA (data not shown). Analyses of the genotypic data, using the mapping service of the UK Human Genome Mapping Program Research Center, have indicated that the mouse Erf gene is localized on chromosome 7 close to the Pkcc anchor marker proximal to the centromere (Lod:3.19). This chromosomal region is syntenic to the human chromosomal 19q13 region where the Pkcc marker is also localized and consistent with our mapping data of the human gene.
(GT) n dinucleotide repeat polymorphism Polymorphic microsatellite sequences serving as molecular markers are particularly useful tools in human chromosome genetic and physical mapping and, potentially, in genotype-phenotype correlations. To identify these sequences, which are closely linked to human ERF, the two overlapping cosmid clones containing the gene, pEW15 no. 20 and pEW15 no. 7 (Figure 1) , were investigated by Southern analysis. A 380 bp HaeIII fragment from pEW15 no. 20 yielded a strong hybridization signal after probing to a synthetic (GT)-19-oligonucleotide. The fragment was partially sequenced (EMBL accession No. X97703) to identify the GT repeat and to provide information for appropriate PCR primers¯anking the repeat. Genotyping across the CEPH (Centre d'Etude du Palymorphigme Humain) parental DNAs determined four alleles, i.e. A1 (167 bp), A2 (169 bp), A3 (171 bp) and A4 (173 bp) (data not shown). The observed heterozygosity was 53%. Allele frequencies estimated from 154 chromosomes of 77 unrelated individuals, i.e. parents of the three generation CEPH (Paris) families, were: 0.30, 0.51, 0.17 and 0.02, respectively. Codominant segretation was observed in seven large CEPH families tested, ie, no. 1333, no. 1340, no. 1344, no. 66, no. 102, no. 1418 and no. 12 , suggesting the stability of the repeat and thus its applicability as an ERF linked microsatellite genetic marker.
Discussion
ERF, a new ets domain protein (Sgouras et al., 1995) , is the ®rst mammalian member of this family that exhibits transcriptional repressor activity. This ERF product has been shown to be regulated by phosphorylation during cell cycle and mitogenic stimulation via the ras/MAPK signaling pathway (Sgouras et al., 1995, and unpublished data) . To this extent, it is analogous to the only other ets-domain protein that has transcriptional repressor function, the Drosophila gene, Yan (ONeill et al., 1994) . Furthermore, ERF has been shown to suppress ets-and fos-induced transformation (Sgouras et al., 1995) and phosphorylation de®cient mutant of ERF can suppress ras-induced transformation (to be published elsewhere). Thus, it would appear that erf may function as a tumorsuppressor gene, suggesting that part of the ets oncogenic phenotype may be associated with the inhibition of erf function.
In order to further our understanding of ERF function, its association with other ets genes and its possible impliction in malignant processes, we have characterized the gene structurally from both human and mouse, determined its chromosomal localization, identi®ed a potentially useful microsatellite polymorphic marker and characterized its promoter region. Structural analysis of the human and mouse genes indicated a high degree of conservation between the two species both at the intron/exon organization and sequence level. This is consistent with our preliminary data indicating that the erf gene can be detected by Southern analysis in species throughout evolution from chicken to man (unpublished data). Comparison between the human and mouse gene suggests that the targets of the gene should be identical in the two species. This is apparent from the identity of the DNA-binding domains. The conservation of all the recognizable motifs, including the MAPK sites and the putative SH3 interaction domains, indicate that the possible regulatory mechanism should also be conserved. Interestingly, a number of mutations can be found in the area previously de®ned as the repressor domain. Since the human gene can eectively repress transcription in mouse cells (Sgouras et al., 1995, and unpublished data) , it is unlikely that these dierences are a result of diverging co-factors required for repressor function. Thus, it is likely that these amino acid dierences provide a more narrow de®nition of the erf repressor domain. However, this hypothesis requires further testing. The DNA-binding domain of erf, as in most of the characterized ets genes, is encoded by two exons (exons II and III). However, the intron-exon boundaries of erf are distinct from other ets genes, indicating an early divergence of erf from the other ets genes in evolution. This observation is consistent with the positioning of ERF in the ets gene evolutionary tree. Computer analysis performed by comparison of the ets-DNA-binding domains of the known ets family members by the PileUp program of the GCG package, positioned erf between Yan and PE-1 (data not shown).
In addition to the structural and sequence conservation of erf between human and mouse, we also observed a conservation in their respective chromosomal positions. Thus, the human gene was localized in chromosome 19q13.1 and the mouse gene in the syntenic position proximal to the centromere of chromosome 7. Both the human chromosome 19 and the mouse chromosome 7 have been associated with a number of abnormal phenotypes. Speci®cally, human chromosome 19 has been associated with a number of hematopoietic malignancies that involve translocations or trisomies (Johanson et al., 1994; Stark et al., 1995) . Although the most common translocation, t(14;19)(q32;q13), involves the BCL3 gene (Tanaka et al., 1990; Yabumoto et al., 1994; Ohno et al., 1993) , a number of case reports referring to abnormalities in chromosome 19q13 have been published (Paietta et al., 1988; Belge et al., 1992; Bartnitzke et al., 1989 ). An increasing volume of data implicates ets genes in lymphoid malignancies, suggesting a role for ets genes in lymphoid development and dierentiation. To this extent, it is plausible that ERF may be involved in some of the malignancies associated with 19q13 abnormalities. Chromosome 19 abnormalities have also been reported in a number of solid tumors in breast, lung and GI tract. Although solid tumors usually display multiple chromosomal abnormalities, it is possible that ERF deregulation may contribute to the transformed phenotype. The possible involvement of ERF in growth regulation suggests that loss or modulation of ERF function may contribute to the proliferative aspect of the malignant phenotype. However, extensive analysis is required in order to establish any possible association of ERF with these cases. Thus, the microsatellite polymorphic marker that we have identi®ed proximal to the ERF gene should facilitate the determination of a possible linkage of ERF with the transforming phenotype.
Another interesting point of the comparison between human and mouse erf is the high degree of conservation in their promoter region. The region that is surrounding the area homologous to the 5' end of the human ERF cDNA is 91% identical between the two species and for the ®rst 150 nt upstream of the cDNA end contain no gaps. The degree of structural conservation in this area is equal to that of the coding regions, and it is in clear contrast to other sequenced areas of the two genes as the second and third introns and the 3' untranslated regions, which have a low degree of similarity (i.e. 50 ± 60%). This region can serve as a promoter in transient transfection assays and contains a number of putative binding sites for transcription factors that are conserved both in sequence and in relative positions, suggesting that the level of ERF transcription may be important. Indeed, in most tissues and cell lines tested, ERF mRNA levels exhibit little dierence and it is not clear at this point whether these minor observed dierences also re¯ect protein levels or are compensatory for protein turnover among dierent cell types. We were unable to detect any dierence in ERF transcription as a function of cell cycle or growth stage (unpublished data) and we could only observe a dramatic decrease in ERF mRNA levels in cultures that were entering density crisis and consequently apoptosis (unpublished data). However, under these conditions most of the cellular transcription is terminated and is unknown at this point whether loss of ERF function might be a contributing factor in this process.
It is of interest that a putative ets-binding site (EBS), adjacent to an Sp1 site, within the ERF promoter is required for promoter function. Although further experiments are required to determine the contribution of the EBS, by itself and in association with the Sp1 site, in the regulation of ERF transcription, it is suggestive of a possible feedback loop in ERF regulation. ERF was isolated by its association with the ETS2 promoter regulatory sequence, and our data indicate that it may itself be regulated by other etsdomain proteins, suggesting an additional level of coordinated regulation among ets family members.
Materials and methods
Isolation and analysis of erf genes
The human placenta cosmid and the bacteriophage lambda 129SVJ libraries were purchased from Stratagene (Cat. Nos. 951202 and 946309, respectively) and were screened according to the protocols of the company. Duplicate ®lters were screened with the entire ERF cDNA as a probe. Restriction mapping, Southern and Northern blot analysis, subcloning and sequencing, as well as all other molecular techniques were performed according to Sambrook et al. (1989) . Total RNA from cell lines and tissues was isolated with RNazol according to the manufacturer's specifications. Computer analysis was performed with the University of Wisconsin GCG package.
Cell lines and transfections
HeLa cells were maintained in DMEM supplemented with 10% bovine serum. P3-HR1, Raji, MOLT4, HL60, RS 4;11, KG1, K562, HGL and Colo320 cells were maintained in RPMI with 15% fetal bovine serum. The cells were transfected with the Calcium Phosphate method according to Gorman et al. (1982) with 1 ± 3 mg reporter plasmid. One mg pCH110 plasmid (Pharmacia) was used to monitor the transfection variation. All transfections were performed at ERF genomic structure D Liu et al least in triplicate with two independent DNA preparations. Determination of CAT activity was performed with a diusion based assay using 14 C-labeled acetyl-CoA (NEN) according to the manufacturer's protocol. DNA fragments to be tested for promoter activity were subcloned at the NotI site of the pUMS P-L vector (Jorcyk et al., 1991) .
Chromosomal mapping
Fluorescence in situ hybridization was performed as described (Tory et al., 1992) . Brie¯y, the two pEW15 genomic clones no. 7 and no. 20 were pooled and labeled with biotin-11-dUTP using nick translation. Hybridization was performed at a probe concentration of 30 ng/microliter at 378C for 16 h followed by washing at 408C in 50% formamide in 26SSC. Slides were then incubated in a detection solution containing 5 mg/ml¯uorescein isothiocyanate (FITC)-conjugated avidin. Chromosome identification was mediated using QFH banding by simultaneous Hoechst 33258 staining.
Genetic linkage analysis
Genetic linkage analysis was performed with the support and technical advice of UK Human Genome Mapping Programme (HGMP), Resource Center which provides the facility based on an interspeci®c backcross between c57BL/6 and Mus spretus for the genetic mapping of mouse probes on the mouse genome (Genome News, 1995) . Genotypic analysis of a panel of about 50 random backcross progeny mice was performed by Southern blots using as a probe a mouse ERF 950 bp KpnI fragment. Earlier, this fragment was found to detect a TaqI polymorphism on Mus spretus and C57BL/6 parental polyblots provided by the Resource Center (data not shown). Linkage to chromosome 7 was carried out at the Resource Center by haplotype ordering. Relevant computation of linkage was obtained through the MBx database where mouse, locus, probe and allele data at each chromosome locus for each of 1000 backcross progeny, are stored.
GT-dinucleotide polymorphism
The oligonucleotides CTGAGGGGTTATTCTGTCTC and AGCCAGGTGCAGAGTAATAC were used to determine a possible (GT) n polymorphism by PCR. The PCR reaction was performed in a volume of 25 ml containing 30 ng of DNA, 35 pmoles of each of the primers, 0.3 pmole of 32 Plabeled GT-strand primer, 250 mM of each dATP, dCTP, dGTP and dTTP, 5 mg BSA, 0.5 U Taq polymerase (Minotech), 10 mM Tris HCl pH 8.3, 50 mM KCl and 1.5 mM MgCl 2 , initial denaturation at 948C (5 min) was followed by 35 cycles with denaturation at 948C (45 s), annealing at 578C (60 s). And extension at 728C (2 min). The ®nal extension step was for 7 min. Products were resolved on 6% polyacrylamide/urea gels. Allele sizes were estimated by comparison to a M13mp18 sequencing ladder. The most intense band for each allele was used to obtain the allele size. Genomic DNA from CEPH families was provided by GENETHON to NKM, in the context of the EUROGEM project.
